Page 20 - ARNM-1-2

Advances in Radiotherapy
& Nuclear Medicine Advancements and challenges in radioactive iodine-125

50. Armpilia CI, Dale RG, Coles IP, et al., 2003, The 60. Podder TK, Beaulieu L, Caldwell B, et al., 2014, AAPM and GEC-
determination of radiobiologically optimized half-lives for ESTRO guidelines for image-guided robotic brachytherapy:
radionuclides used in permanent brachytherapy implants. Report of Task Group 192. Med Phys, 41: 101501.
Int J Radiat Oncol Biol Phys, 55: 378–385. https://doi.org/10.1118/1.4895013
https://doi.org/10.1016/s0360-3016(02)04208-6 61. Liu S, Wang H, Wang C, et al., 2019, Dosimetry verification
51. Manimaran S, 2007, Radiobiological equivalent of low/ of 3D-printed individual template based on CT-MRI fusion
high dose rate brachytherapy and evaluation of tumor and for radioactive (125)I seed implantation in recurrent high-
normal responses to the dose. Radiat Med, 25: 229–235. grade gliomas. J Contemp Brachytherapy, 11: 235–242.
https://doi.org/10.1007/s11604-007-0131-9 https://doi.org/10.5114/jcb.2019.85729
52. Patankar SS, Tergas AI, Deutsch I, et al., 2015, High versus 62. Major T, Polgár C, Jorgo K, et al., 2017, Dosimetric
low-dose rate brachytherapy for cervical cancer. Gynecol comparison between treatment plans of patients treated
Oncol, 136: 534–541. with low-dose-rate vs. high-dose-rate interstitial prostate
brachytherapy as monotherapy: Initial findings of a
https://doi.org/10.1016/j.ygyno.2014.12.038 randomized clinical trial. Brachytherapy, 16: 608–615.
53. Cagetti LV, Zemmour C, Salem N, et al., 2019, High-dose- https://doi.org/10.1016/j.brachy.2017.02.003
rate vs. low-dose-rate interstitial brachytherapy boost for
anal canal cancers. Brachytherapy, 18: 814–822. 63. Zhang H, Liang Y, Qiu G, et al., 2019, Precision dose
measurement of 125I seed in solid water through SPECT/
https://doi.org/10.1016/j.brachy.2019.08.005 CT detecting. J Cancer Res Ther, 15: 291–297.
54. Nath R, Anderson LL, Luxton G, et al., 1995, Dosimetry of https://doi.org/10.4103/jcrt.JCRT_522_18
interstitial brachytherapy sources: recommendations of the 64. Zhang H, Zhao X, Wang J, et al., 2016, Dose distribution
AAPM Radiation Therapy Committee Task Group No. 43. detected by SPECT/CT in a patient with prostate cancer
American Association of Physicists in Medicine. Med Phys, treated with 125I seeds: A case report. Brachytherapy, 15:
22: 209–234. S183–S184.
https://doi.org/10.1118/1.597458 https://doi.org/10.1016/j.brachy.2016.04.337
55. Li R, Ying Z, Yuan Y, et al., 2019, Comparison of two 65. Kono Y, Miyamoto Y, Oohashi S, et al., 2011, Radiation
iodine-125 brachytherapy implant techniques for the exposure to general public after permanent brachytherapy
treatment of lung tumor: Preplanning and intraoperative for prostate cancer. Radiat Prot Dosimetry, 146: 229–230.
planning. Brachytherapy, 18: 87–94.
https://doi.org/10.1093/rpd/ncr156
https://doi.org/10.1016/j.brachy.2018.08.007
66. Herrera FG, Bourhis J, Coukos G, 2017, Radiotherapy
56. Loftus TP, 1984, Exposure standardization of Iodine-125 combination opportunities leveraging immunity for the
seeds used for brachytherapy. J Res Natl Bur Stand (1977), next oncology practice. CA Cancer J Clin, 67: 65–85.
89: 295–303.
https://doi.org/10.3322/caac.21358
https://doi.org/10.6028/jres.089.017
67. Pencik J, Schlederer M, Gruber W, et al., 2015, STAT3
57. DeWerd LA, Huq MS, Das IJ, et al., 2004, Procedures for regulated ARF expression suppresses prostate cancer
establishing and maintaining consistent air-kerma strength metastasis. Nat Commun, 6: 7736.
standards for low-energy, photon-emitting brachytherapy https://doi.org/10.1038/ncomms8736
sources: Recommendations of the Calibration Laboratory
Accreditation Subcommittee of the American Association 68. Formenti SC, Demaria S, 2013, Combining radiotherapy
of Physicists in Medicine. Med Phys, 31: 675–681. and cancer immunotherapy: A paradigm shift. J Natl Cancer
Inst, 105: 256–265.
https://doi.org/10.1118/1.1645681
https://doi.org/10.1093/jnci/djs629
58. Perez-Calatayud J, Ballester F, Das RK, et al., 2012, Dose
calculation for photon-emitting brachytherapy sources with 69. Finkelstein SE, Salenius S, Mantz CA, et al., 2015, Combining
average energy higher than 50 keV: Report of the AAPM immunotherapy and radiation for prostate cancer. Clin
and ESTRO. Med Phys, 39: 2904–2929. Genitourin Cancer, 13: 1–9.
https://doi.org/10.1118/1.3703892 https://doi.org/10.1016/j.clgc.2014.09.001
59. Nath R, Anderson LL, Meli JA, et al., 1997, Code of practice 70. Du E, Wang L, Li CY, et al., 2017, Analysis of immune
for brachytherapy physics: Report of the AAPM Radiation status after iodine-125 permanent brachytherapy in prostate
Therapy Committee Task Group No. 56. American Association cancer. Onco Targets Ther, 10: 2561–2567.
of Physicists in Medicine. Med Phys, 24: 1557–1598. https://doi.org/10.2147/OTT.S137491

Volume 1 Issue 2 (2023) 12 https://doi.org/10.36922/arnm.0914